Literature DB >> 22065074

Correlation of serum prolactin levels and disease activity in systematic lupus erythematosus.

Mansoor Karimifar1, Afshin Tahmasebi, Zahra Sayed Bonakdar, Samaneh Purajam.   

Abstract

To assess the frequency of hyperprolactinaemia and its possible clinical significance in patients with systemic lupus erythematosus (SLE). In this cross-sectional study, we determined serum prolactin (PRL) levels in 60 SLE female patients (age range 15-60 years). Disease activity was defined according to the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Serum PRL concentrations were determined by immunoradiometric assay. Elevated serum concentrations of PRL (>20 ng/ml) were found in 5 of 60 (8.4%) patients. No direct correlation between PRL levels with disease activity of SLE was found (r = 0.062, P = 0.39). SLE was active in 23 patients (SLEDAI ≥ 6) and inactive in 37 (SLEDAI < 6). In those with active disease, median PRL levels were lower (11.0 ng/ml) than normoprolactinaemic group (12.1 ng/ml). There was no significant difference in serum PRL levels between active and non-active patients (P = 0.07). There was a significant difference in the frequency of several clinical manifestations and serological parameters between SLE patients with normal and high prolactin (renal involvement, haematological manifestation and anti-ds DNA). This study has shown that hyperprolactinaemia is prevalent in random SLE patients. The elevated PRL levels seem not to be associated with disease activity. The mechanism and pathoaetiological and clinical significance of hyperprolactinaemia in a small subset of SLE patients remain unclear and a longer follow-up is necessary.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22065074     DOI: 10.1007/s00296-011-2211-5

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  47 in total

1.  Elevated bioactive prolactin levels in systemic lupus erythematosus--association with disease activity.

Authors:  M Pacilio; S Migliaresi; R Meli; L Ambrosone; B Bigliardo; R Di Carlo
Journal:  J Rheumatol       Date:  2001-10       Impact factor: 4.666

2.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

3.  Antiprolactin autoantibodies in systemic lupus erythematosus: frequency and correlation with prolactinemia and disease activity.

Authors:  A Leaños-Miranda; D Pascoe-Lira; K A Chávez-Rueda; F Blanco-Favela
Journal:  J Rheumatol       Date:  2001-07       Impact factor: 4.666

4.  Prolactin receptors on human T and B lymphocytes: antagonism of prolactin binding by cyclosporine.

Authors:  D H Russell; R Kibler; L Matrisian; D F Larson; B Poulos; B E Magun
Journal:  J Immunol       Date:  1985-05       Impact factor: 5.422

5.  Pituitary function in patients with newly diagnosed untreated systemic lupus erythematosus.

Authors:  M D Köller; E Templ; M Riedl; M Clodi; O Wagner; J S Smolen; A Luger
Journal:  Ann Rheum Dis       Date:  2004-04-13       Impact factor: 19.103

6.  Prolactin levels and antinuclear antibody profiles in women tested for connective tissue disease.

Authors:  S H Allen; G C Sharp; G Wang; C Conley; Y Takeda; S E Conroy; S E Walker
Journal:  Lupus       Date:  1996-02       Impact factor: 2.911

7.  Prolactin and gonadal hormones during pregnancy in systemic lupus erythematosus.

Authors:  L Jara-Quezada; A Graef; C Lavalle
Journal:  J Rheumatol       Date:  1991-03       Impact factor: 4.666

8.  Prolactin-induced mitogenesis of lymphocytes from ovariectomized rats.

Authors:  S M Viselli; E M Stanek; P Mukherjee; W C Hymer; A M Mastro
Journal:  Endocrinology       Date:  1991-08       Impact factor: 4.736

9.  Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus.

Authors:  R W McMurray; D Weidensaul; S H Allen; S E Walker
Journal:  J Rheumatol       Date:  1995-11       Impact factor: 4.666

10.  Hyperprolactinaemia in patients with systemic lupus erythematosus.

Authors:  L Moszkorzová; Z Lacinová; J Marek; L Musilová; A Dohnalová; C Dostál
Journal:  Clin Exp Rheumatol       Date:  2002 Nov-Dec       Impact factor: 4.473

View more
  7 in total

1.  Serum prolactin levels in patients with psoriasis: Results of a pilot study.

Authors:  Gaytri Khatri; Vikram K Mahajan; Karaninder S Mehta; Krishan Kumar Sharma; Satya Bhushan; Pushpinder S Chauhan
Journal:  Indian J Med Res       Date:  2017-02       Impact factor: 2.375

2.  Autoimmune hypothyroidism is three times more frequent in female prolactinoma patients compared to healthy women: data from a cross-sectional case-control study.

Authors:  Atanaska Elenkova; Iliana Аtanasova; Georgi Кirilov; Еmil Natchev; Ralitza Ivanova; Roussanka Кovatcheva; Silvia Vandeva; Dimitar Tcharaktchiev; Sabina Zacharieva
Journal:  Endocrine       Date:  2017-07-19       Impact factor: 3.633

3.  Prevalence of autoimmune disease in patients with prolactinomas and non-functioning pituitary adenomas.

Authors:  V Larouche; J A Correa; P Cassidy; C Beauregard; N Garfield; J Rivera
Journal:  Pituitary       Date:  2016-04       Impact factor: 4.107

4.  Prolactin rescues and primes autoreactive B cells directly and indirectly through dendritic cells in B6.Sle3 mice.

Authors:  J Gonzalez; S Saha; E Peeva
Journal:  Clin Exp Immunol       Date:  2013-05       Impact factor: 4.330

5.  Morbidity and mortality in patients with hyperprolactinaemia: the PROLEARS study.

Authors:  Enrique Soto-Pedre; Paul J Newey; John S Bevan; Graham P Leese
Journal:  Endocr Connect       Date:  2017-11       Impact factor: 3.335

6.  Association of extrapituitary prolactin promoter polymorphism with disease susceptibility and anti-RNP antibodies in Mexican patients with systemic lupus erythematosus.

Authors:  Jorge Hernández-Bello; Claudia A Palafox-Sanchez; Samuel García-Arellano; Zyanya Reyes-Castillo; Ana L Pereira-Suárez; Isela Parra-Rojas; José E Navarro-Zarza; Ulises De la Cruz-Mosso; Nora M Torres-Carrillo; José Francisco Muñoz-Valle
Journal:  Arch Med Sci       Date:  2016-09-02       Impact factor: 3.318

7.  Prolactin Rescues Immature B-Cells from Apoptosis Induced by B-Cell Receptor Cross-Linking.

Authors:  Rocio Flores-Fernández; Francisco Blanco-Favela; Ezequiel M Fuentes-Pananá; Luis Chávez-Sánchez; Patricia Gorocica-Rosete; Alberto Pizaña-Venegas; Adriana Karina Chávez-Rueda
Journal:  J Immunol Res       Date:  2016-05-24       Impact factor: 4.818

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.